Medically reviewed by Jurairat J. Molina, MD Acute urticaria (hives) is a common skin condition that affects up to 20% of people at some point in their lives. It can transition into chronic urticaria ...

The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.

Dupilumab (Dupixent), a fully human monoclonal antibody that targets the interleukin (IL)-4 and IL-13 pathways, is currently ...

The mainstay of treatment for urticaria is oral antihistamines as ... If possible, it is best to avoid all antihistamines in pregnancy, although none has proven teratogenic. If one is used ...

Jasper Therapeutics faces financial challenges but strong buy ratings. Read why JSPR stock is poised for growth amid risks ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window BOSTON -- Add-on dupilumab (Dupixent) significantly reduced ...

Dr. Joshua Simmons, an Army colonel and physician to the vice president, also said the VP has a history of seasonal allergies and urticaria ... the “optimal treatment for controlling her ...

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...

Dr. Joshua Simmons, an Army colonel and physician to the vice president, also said the vice president has a history of seasonal allergies and urticaria, or hives, which he described as ...

The rising prevalence of urticaria is fueling market growth, with increased allergic responses and lifestyle shifts playing key roles. Advances in biologic treatments and a strong development ...

and others are evaluating new urticaria drugs to improve the treatment landscape. Promising pipeline urticaria therapies such as Dupilumab, TAS5315, AK006, YH35324, UB-221, TLL-018, KPL-716, AK002, ...